pSivida Corp (PSDV) Names James Barry To Board Of Directors

pSivida Corp (PSDV) Names James Barry To Board Of Directors

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors.

Dr. Barry, age 55, currently serves as Executive Vice President and Chief Operating Officer of InspireMD, a global medical device company focused on the development and commercialization of cardiovascular products. At InspireMD, Dr. Barry is responsible for advancing the product pipeline, managing all global clinical trial activities and driving the operational activities. 

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.